Gilead Sciences (NASDAQ: [[ticker:GILD]]), the world’s largest maker of HIV drugs, said it has formed a new cancer research collaboration with Yale University. Under the deal, Foster City, CA-based Gilead will provide $40 million to support research over the first four years, and has the option to extend the collaboration for 10 years, and a total of $100 million. Gilead will have the first shot at commercializing inventions that arise at Yale from the partnership. The research alliance is the latest move ahead for Gilead in cancer, coming on the heels of its acquisition of Seattle-based Calistoga Pharmaceuticals for as much as $600 million.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
